Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase‐driven adaptive dosing of 5‐FU in patients with digestive cancer

AIMS: 5‐FU is the backbone of most regimens in digestive oncology. Administration of standard 5‐FU leads to 15–30% of severe side effects, and lethal toxicities are regularly reported with fluoropyrimidine drugs. Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome responsi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Launay, Manon, Dahan, Laetitia, Duval, Manon, Rodallec, Anne, Milano, Gérard, Duluc, Muriel, Lacarelle, Bruno, Ciccolini, Joseph, Seitz, Jean‐Francois
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2015
Témata:
Pharmacogenetics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4693577/
https://ncbi.nlm.nih.gov/pubmed/26392323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12790
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky